This review highlights current treatments, controversies surrounding vasoactive therapies, and future directions for managing acute decompensated heart failure.
Answers are grounded in this paper and cite their sources.
Does not warrant practice changes in acute decompensated HF; leaves open vasoactive therapy controversies for prospective trials.
Acute decompensated heart failure is a growing public health care problem worldwide. The goals of treatment are immediate hemodynamic and symptomatic improvement followed by persistent follow-up with adherence to chronic heart failure guidelines. Controversies have centered around the best treatment options and avoidance of serious adverse events. This article highlights our current understanding of acute decompensated heart failure, discusses the controversy surrounding currently available new vasoactive treatments, and details future potential therapies.
No takes yet. Share an insight, caveat, or question.
Mark Munger (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: